Geneva Partners’s Zimmer Biomet ZBH Stock Holding History

Geneva Partners’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,056	Closed	-$202K	–	86
2020 Q1	$202K	Buy	+2,056	New	+$270K	0.29%	48

Other funds holding ZBH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geneva Partners's ZBH Position: Q2 2020 in Review

Geneva Partners sold out of Zimmer Biomet (ZBH) in Q2 2020, closing a stake of 2,056 shares — an estimated $202K sold.

Geneva Partners first reported a position in ZBH in Q1 2020 and held it in 1 quarter. The position peaked at $202K in Q1 2020. 945 funds tracked by Wall St. Rank hold ZBH as of Q2 2020.

Geneva Partners reported no remaining Zimmer Biomet position as of Q2 2020 after selling out during the quarter.
Geneva Partners sold 2,056 Zimmer Biomet shares in Q2 2020, an estimated $202K.
Geneva Partners first reported a position in Zimmer Biomet in Q1 2020 and held it in 1 quarter.
Geneva Partners's Zimmer Biomet position peaked at $202K in Q1 2020.
945 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2020.

Based on Geneva Partners's 13F filing for Q2 2020, filed 20 Jul 2020.